NR4A1 and breast carcinoma: Endocrine therapy is the preferred treatment for patients with stage III or IV hormone-receptor-positive (HR +, which includes ER and/or PR positive) breast cancer, but chemotherapy may also be recommended for cases with rapidly progressive disease [4,5].